Use of Lactate-to-Albumin, CRP-to-Albumin, and Procalcitonin-to-Albumin Ratios to Predict Mortality in ICU Patients (LAR-CAR-PAR)

November 18, 2025 updated by: Medical University of Silesia

Lactate-to-albumin, CRP-to-albumin and Procalcitonin-to-albumin Ratios Predict Mortality in Critically Ill Adults: a Retrospective ICU Cohort Study

This observational study aims to determine whether three blood test ratios - lactate-to-albumin, CRP-to-albumin, and procalcitonin-to-albumin - can predict in-hospital mortality among critically ill adults. The study includes all adult patients admitted in 2024 to the ICU Ward B at the Silesian Center for Heart Diseases (SCCS) in Zabrze. Researchers will analyze retrospective clinical and laboratory data from electronic medical records, including lab values collected at ICU admission, patient demographics, diagnoses, and outcomes. The biomarker ratios will be manually calculated in Excel and statistically evaluated. The main goal is to assess whether these ratios are associated with patient survival and to identify predictive cut-off values to support early risk stratification in the ICU setting.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

212

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Poland
    • Silesian Voivodeship
      • Zabrze, Silesian Voivodeship, Poland, 41-800
        • Department of Acute Medicine, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Poland

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Adult patients admitted to the ICU. Data collected retrospectively from clinical records (AMMS system).

Description

Inclusion Criteria:

  • Age ≥ 18 years
  • Admission to ICU in 2024
  • Availability of data for lactate, CRP, procalcitonin, and albumin

Exclusion Criteria:

  • Missing outcome data (e.g. unknown survival status)
  • Lack of laboratory parameters necessary for ratio calculation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Survivors
Critically ill adult patients admitted to the ICU who survived hospitalization and were discharged alive.
Non-Survivors
Critically ill adult patients admitted to the ICU who died during the course of hospitalization.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
In-hospital mortality
Time Frame: 100 days from the date of ICU admission
All-cause in-hospital mortality among ICU patients during the index hospitalization.
100 days from the date of ICU admission

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Medical University of Silesia

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 21, 2025

Primary Completion (Actual)

July 25, 2025

Study Completion (Actual)

September 20, 2025

Study Registration Dates

First Submitted

September 15, 2025

First Submitted That Met QC Criteria

November 18, 2025

First Posted (Actual)

November 21, 2025

Study Record Updates

Last Update Posted (Actual)

November 21, 2025

Last Update Submitted That Met QC Criteria

November 18, 2025

Last Verified

August 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • SUM-SKNIPG-LARCARPAR-ICU-2025

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

The individual participant data (IPD) will not be shared due to the retrospective nature of the study and the use of sensitive patient health records. The dataset is not publicly available, and consent for external data sharing was not obtained from participants or their legal representatives.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Sepsis

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Pakistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe